Lerdelimumab

Lerdelimumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TGF beta 2
Clinical data
ATC code	none;
Legal status
Legal status	Development discontinued;
Identifiers
CAS Number	285985-06-0 ;
ChemSpider	none;
(what is this?) (verify)

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]

References

"Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
"CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. 3 (2): 106–108. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.

[2] "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.